medigraphic.com
Colegio de Medicina Interna de México.

2023, Number 3

<< Back Next >>

Med Int Mex 2023; 39 (3)

IMPROVE Bleeding Risk Score in patients with thromboprophylaxis of deep vein thrombosis

Martínez-Sánchez LM, Durango-Sánchez C, Morales-Montoya A, Thowinson-Hernández MC, Carvajal-Alzate M, Roldan-Isaza M, Cuartas-Agudelo YS

Language: Spanish
References: 17
Page: 448-453
PDF size: 199.32 Kb.


ABSTRACT

Objective: To characterize clinically and epidemiologically the patients with diagnosis of deep vein thrombosis and their risk of bleeding in a tertiary level institution in the city of Medellin, Colombia.
Materials and Methods: A cross-sectional, descriptive, observational study was done including patients with a diagnosis of deep vein thrombosis and thromboprophylactic treatment from 2018 to 2019. A non-probabilistic sampling of consecutive cases was performed.
Results: There were included 26 patients; the median age was 64.5 years and female sex predominated (22/26). The presence of solid tumor was evidenced in 3 patients; 21 had previous venous thromboembolism and no history of thrombophilia was reported. The main complication was short-term deep venous thrombosis in 11 patients; 11 patients were classified by the IMPROVE Bleeding Risk Score, where a high risk of bleeding was identified in 3 of them. Of the 26 patients studied, 22 were hospitalized in the general ward and 2 died.
Conclusions: Patients diagnosed with deep vein thrombosis and thromboprophylactic therapy may present an important bleeding risk, which should be constantly assessed, as this may have an impact on patient outcomes.


REFERENCES

  1. Wenger N, Sebastian T, Engelberger RP, Kucher N, Spirk D.Pulmonary embolism and deep vein thrombosis: Similarbut different. Thromb Res 2021; 206: 88-98. doi: 10.1016/j.thromres.2021.08.015.

  2. Di Nisio M, van Es N, Büller HR. Deep vein thrombosis andpulmonary embolism. Lancet 2016; 388 (10063): 3060-73.doi: 10.1016/S0140-6736(16)30514-1.

  3. Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism.Lancet 2021; 398 (10294): 64-77. doi:10.1016/S0140-6736(20)32658-1.

  4. Chopard R, Albertsen IE, Piazza G. Diagnosis andtreatment of lower extremity venous thromboembolism:a review. JAMA 2020; 324 (17): 1765-76. doi: 10.1001/jama.2020.17272.

  5. Villarreal JV, Shibuya N, Jupiter DC. Thromboprophylaxisand bleeding complications in orthopedic and traumapatients: a systematic review. J Foot Ankle Surg 2021; 60(5): 1014-22. doi: 10.1053/j.jfas.2021.03.010.

  6. Schizodimos T, Soulountsi V, Iasonidou C, Kapravelos N.Thromboprophylaxis in critically ill patients: balancing ona tightrope. Minerva Anestesiol 2021; 87 (11): 1239-54.doi: 10.23736/S0375-9393.21.15755-4.

  7. Zhang Z, Zhai Z, Li W, Qin X, Qu J, Shi Y, et al. DissolVE-2investigators. Validation of the IMPROVE bleeding riskscore in Chinese medical patients during hospitalization:Findings from the dissolve-2 study. Lancet Reg Health WestPac 2020; 4: 100054. doi: 10.1016/j.lanwpc.2020.100054.

  8. Evensen LH, Folsom AR, Pankow JS, Hansen JB, Allison MA,Cushman M, et al. Hemostatic factors, inflammatory markers,and risk of incident venous thromboembolism: TheMulti-Ethnic Study of Atherosclerosis. J Thromb Haemost2021; 19 (7): 1718-28. doi: 10.1111/jth.15315.

  9. Konstantinides SV, Meyer G, Becattini C, Bueno H, GeersingGJ, Harjola VP, et al. ESC Scientific Document Group. 2019ESC Guidelines for the diagnosis and management of acutepulmonary embolism developed in collaboration with theEuropean Respiratory Society (ERS). Eur Heart J 2020; 41(4): 543-603. doi: 10.1093/eurheartj/ehz405.

  10. Olaf M, Cooney R. Deep venous thrombosis. EmergMed Clin North Am 2017; 35 (4): 743-70. doi: 10.1016/j.emc.2017.06.003.

  11. Urbanek T, Labropoulos N. Can we predict and prevent thepostthrombotic syndrome? Vasa 2021; 50 (1): 11-21. doi:10.1024/0301-1526/a000932.

  12. Bozzato S, Galli L, Ageno W. Thromboprophylaxis in surgicaland medical patients. Semin Respir Crit Care Med 2012; 33(2): 163-75. doi: 10.1055/s-0032-1311795.

  13. Depietri L, Marietta M, Scarlini S, Marcacci M, CorradiniE, Pietrangelo A, et al. Clinical impact of application ofrisk assessment models (Padua Prediction Score andImprove Bleeding Score) on venous thromboembolism,major hemorrhage and health expenditure associated withpharmacologic VTE prophylaxis: a “real life” prospectiveand retrospective observational study on patients hospitalizedin a Single Internal Medicine Unit (the STIME study).Intern Emerg Med 2018; 13 (4): 527-534. doi: 10.1007/s11739-018-1808-z.

  14. Rosenberg DJ, Press A, Fishbein J, Lesser M, McCullagh L,McGinn T, et al. External validation of the IMPROVE BleedingRisk Assessment Model in medical patients. ThrombHaemost 2016; 116 (3): 530-6. doi: 10.1160/TH16-01-0003.

  15. Hostler DC, Marx ES, Moores LK, Petteys SK, Hostler JM,Mitchell JD, et al. Validation of the International MedicalPrevention Registry on Venous Thromboembolism BleedingRisk Score. Chest 2016; 149 (2): 372-9. doi: 10.1378/chest.14-2842.

  16. Martínez-Montalvo CM, Mondragón-Cardona Á,Maluche-Osorio A, Tovar-Medina JP, Salamanca-MuñozDF, Trujillo-Silva GC, et al. Experiencia en el uso de tromboprofilaxisfarmacológica en un hospital colombianode tercer nivel. Acta médica Perú [Internet] 2018; 35(2): 108-15. Disponible en: http://dx.doi.org/10.35663/amp.2018.352.442.

  17. Romero J, Arias RM, Amaya R, Naranjo F. Uso de tromboprofilaxisen pacientes con patología médica. Revista Colombianade Cardiología 2016; 23: 375-82. Doi: 10.1016/j.rccar.2016.04.008.




2020     |     www.medigraphic.com